home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

34.15 +0.28 (+0.83%)

Streaming Delayed Price Updated: 10:10 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

3 Biotech Stocks to Dump Before They Go to Zero ↗

April 09, 2024

These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.

Via InvestorPlace

RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm

March 11, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023 ↗

March 07, 2024

RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

RAPT Therapeutics: Q4 Earnings Insights ↗

March 07, 2024

Via Benzinga

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

March 07, 2024

Company maintains solid cash position of $158.9 million

From RAPT Therapeutics, Inc.

Via GlobeNewswire

Recap: RAPT Therapeutics Q3 Earnings ↗

November 13, 2023

Via Benzinga

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

March 05, 2024

Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

February 26, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Rivian Automotive Reports Q4 Loss, Joins Etsy, Lucid Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

February 22, 2024

U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday.

Via Benzinga

What's Going On With RAPT Therapeutics Stock On Wednesday? ↗

February 21, 2024

Latest developments in RAPT Therapeutics as FDA places clinical hold on Phase 2b trial for zelnecirnon in dermatitis and asthma. Stock rebounds and analyst downgrades.

Via Benzinga

Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 21, 2024

Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

February 21, 2024

Via Benzinga

Stocks Slip Ahead Of Fed Minutes, Nvidia Earnings ↗

February 21, 2024

Stocks are lower today, with the Nasdaq Composite Index (IXIC) leading the losses as investors reassess a potentially overvalued tech sector.

Via Talk Markets

Topics Economy Stocks

Crude Oil Moves Lower; Summit Therapeutics Shares Plummet ↗

February 20, 2024

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 200 points on Tuesday. The Dow traded down 0.18% to 38,557.86 while the NASDAQ fell 1.30% to 15,570.84. The...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 20, 2024

Via Benzinga

Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today? ↗

February 20, 2024

FDA places clinical hold on RAPT Therapeutics' Phase 2 trials for zelnecirnon in atopic dermatitis and asthma.

Via Benzinga

Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests ↗

February 20, 2024

The FDA put studies in eczema and asthma treatment on clinical hold.

Via Investor's Business Daily

Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 20, 2024

Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.

Via Benzinga

Dow Dips Over 100 Points; US Leading Economic Index Falls In January ↗

February 20, 2024

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.35% to 38,494.51 while the NASDAQ fell 1.51% to 15,537.95. The S&P 500...

Via Benzinga

Topics Stocks

Dow Rebounds; Nasdaq Drops Triple Digits ↗

February 20, 2024

Nvidia stock is sliding ahead of tomorrow's earnings report

Via Talk Markets

Topics Stocks

Nasdaq Down 1%; Capital One Set To Buy Discover ↗

February 20, 2024

U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.05% to 38,607.53 while the NASDAQ fell...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 20, 2024

Via Benzinga

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

February 20, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

February 13, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 31, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

November 27, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

November 13, 2023

Company maintains strong cash position of $184.8 million

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

November 03, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

November 01, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com